ORR at 6 months after ALZ treatments performed in patients with AA, according to risk factor
| N = 64 treatments . | ORR (%) . | P value . |
|---|---|---|
| Age, y | ||
| <65 | 67 | .03 |
| >65 | 31 | |
| Severity of AA | ||
| Nonsevere | 53 | .76 |
| Severe | 61 | |
| Hemoglobin level before treatment | ||
| >7.5 g/dL | 84 | .01 |
| ≤7.5 g/dL | 46 | |
| Platelet count before treatment | ||
| >20 × 109/L | 84 | .03 |
| ≤20 × 109/L | 48 | |
| Presence of a PNH clone | ||
| Yes | 61 | .79 |
| No | 57 | |
| ALZ dose | ||
| 103 mg | 70 | .03 |
| Other doses | 38 | |
| Line of treatment using ALZ | ||
| First | 60 | .73 |
| Second | 65 | |
| Third or more | 50 |
| N = 64 treatments . | ORR (%) . | P value . |
|---|---|---|
| Age, y | ||
| <65 | 67 | .03 |
| >65 | 31 | |
| Severity of AA | ||
| Nonsevere | 53 | .76 |
| Severe | 61 | |
| Hemoglobin level before treatment | ||
| >7.5 g/dL | 84 | .01 |
| ≤7.5 g/dL | 46 | |
| Platelet count before treatment | ||
| >20 × 109/L | 84 | .03 |
| ≤20 × 109/L | 48 | |
| Presence of a PNH clone | ||
| Yes | 61 | .79 |
| No | 57 | |
| ALZ dose | ||
| 103 mg | 70 | .03 |
| Other doses | 38 | |
| Line of treatment using ALZ | ||
| First | 60 | .73 |
| Second | 65 | |
| Third or more | 50 |
Boldface values indicate statitstical significance.